Related Experiment Video
Updated: May 22, 2026
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
Published on: November 14, 2014
[Botulinum toxin type-A toxin activity on prostate cancer cell lines]
Silvia Proietti1, Vincenza Nardicchi, Massimo Porena
1Clinica Urologica ed Andrologica, Università degli Studi di Perugia, Perugia, Italy. sproietti81@libero.it
Aim Of The Study:
Botulinum toxin A (BoNT/A) has been recently used in the treatment of benign prostatic hyperplasia due to its apoptotic activity on prostatic epithelium but few data exist on this issue in prostate cancer. Also no information exist on the eventual modulation exerted by the neurotoxin on Phospholipase A2 (PLA2) expression in prostate cancer. The aim of this study was to evaluate the activity of BoNT/A on cell growth and expression of PLA2 in prostate cancer lines.
Materials And Methods:
PC-3 and LNCaP cell lines were exposed to BoNT/A (Xeomin®), different doses and time of exposure. Presence of SV2 receptors (SV2-A and SV2-B) for the neurotoxin was also investigated. The expression of P-Ser505-cPLA2-α (phosphorylated enzyme) was performed immunofluorescence.
Results:
After 96 hours of BoNT/A administration a 20% reduction of cell growth in LNCaP and 25% in PC-3 were observed. SV-2 receptors were expressed in both cell lines. No cPLA2-α total expression was found in LnCaP. In PC-3 there was a high expression of cPLA2-α total which was not modified after BoNT/A treatment. In both LNCap and PC-3 the expression of P-Ser505-cPLA2-α (phosphorylated enzyme) increases significantly after treatment with [10 U/ml] of BoNT/A.
Conclusions:
LNCaP and PC-3 cell lines are sensitive to treatment with BoNT/A which probably enters the cells by SV2 receptors. The increase in the phosphorylated form of cPLA2-a, induced by BoNT/A may represent one mechanism by which the toxin reduces cell growth and proliferation.
Insights
Botulinum toxin A (BoNT/A) reduces prostate cancer cell growth by increasing the phosphorylated form of Phospholipase A2 (PLA2). This neurotoxin enters cancer cells via SV2 receptors, offering a potential new therapeutic avenue.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Context:
- Botulinum toxin A (BoNT/A) shows promise in treating benign prostatic hyperplasia.
- Limited data exist on BoNT/A's effects in prostate cancer, particularly regarding Phospholipase A2 (PLA2) modulation.
- Prostate cancer cell lines (PC-3 and LNCaP) were utilized to investigate these effects.
Purpose:
- To evaluate the impact of BoNT/A on prostate cancer cell growth.
- To assess the modulation of PLA2 expression by BoNT/A in prostate cancer cell lines.
- To investigate the role of SV2 receptors in BoNT/A uptake.
Summary:
- BoNT/A treatment led to a significant reduction in cell growth for both LNCaP (20%) and PC-3 (25%) cell lines after 96 hours.
- SV2 receptors, crucial for neurotoxin entry, were detected in both cell lines.
- While total cPLA2-α expression remained unchanged in PC-3 and absent in LNCaP, BoNT/A significantly increased the phosphorylated form (P-Ser505-cPLA2-α) in both cell types.
Impact:
- BoNT/A demonstrates sensitivity in prostate cancer cell lines, likely entering via SV2 receptors.
- The observed increase in phosphorylated cPLA2-α suggests a key mechanism by which BoNT/A inhibits cancer cell proliferation.
- These findings support further research into BoNT/A as a potential therapeutic agent for prostate cancer.
More Related Videos
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
01:12Bacterial Toxins